Latest news

Contera Pharma and BDD Pharma announce dosing of first subject in a Phase 1 trial of CP-012, a novel formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease

BDD Pharma Ltd Unveils Updated Logo for 2023

Latest blog posts

Eliminating Unnecessary Steps with Lean Clinical Development™

MCC Propellant Testing. CPHI & PODD conferences.